

## 2015 Profile of Invasive *Streptococcus pneumoniae* in Dallas County Dallas County Health and Human Services

Summary of Invasive S. pneumoniae Cases, 2015

Cases

ę


Number

35


Number of Cases


	n (%)	Incidence per 100,000
Total	190	7.4
Sex		
Male	95 (50.0)	7.6
Female	95 (50.0)	7.3
Race/Ethnicity		
Hispanic	35 (18.4)	3.5
White	89 (46.8)	11.2
Black	61 (32.1)	10.6
Asian	5 (2.6)	3.1
American Indian	0	N/A
Age Group (years)		
<1	7 (3.7)	17.7
1-4	7 (3.7)	4.5
5-9	3 (1.6)	1.5
10-14	0	N/A
15-19	2 (1.1)	1.2
20-29	8 (4.2)	2.0
30-39	15 (7.9)	3.9
40-49	35 (18.4)	10.3
50-59	42 (22.1)	13.3
≥60	71 (37.4)	19.0
Hospitalizations	106 (55.8)	4.2
Deaths	9 (4.7)	4.6
Clinical Syndrome	n	(%)
Primary Bacteremia	167	87.9
Pneumonia	11	5.8
Empyema	2	1.1
Meningitis	2	1.1
Septic arthritis	1	0.5
Primary bacteremia and pneumonia	3	1.6
Primary meningitis and pneumonia	1	0.5
Other*	3	1.6


Invasive S. pneumoniae Cases and Incidence by Year of Onset, Dallas County, 2003-2015



Invasive S. pneumoniae Cases and Incidence by Sex and Age Group (years), 2015








 Invasive pneumococcal disease is identified by isolation of S. penumonia bacteria from a normally sterile body site (e.g., blood, cerebrospinal fluid, or pleural fluid). The major clinical syndromes caused by S. pneumoniae are pneumonia, bacteremia, and meningitis.

- immunosuppression.
- years.



N/A = Not applicable

DCHHS Epidemiology

\* Includes abscess, osteomyelitis, and otitis media

Note: Incidence calculated using projected population data for 2015

Data Sources: Dallas County Department of Health and Human Services, Epidemiology Division; National Electronic Disease Surveillance System (NEDSS); Population data obtained through the Centers for Disease Control and Prevention: WONDER Bridged-Race Population Estimates 1990-2015.

## Summary

 Persons with increased risk of invasive pneumococcal disease include children less than 5 years old who attend daycare, and persons with cochlear implants, functional asplenia, or chronic heart, kidney or lung disease, or

 Pneumococcal conjugate vaccine (PCV13) is recommended for children younger than five and newly recommended for all adults ≥65 years. The pneumococcal polysaccharide vaccine (PPSV23) is also recommended for adults ≥65

**Distribution of Invasive**